Cergentis

3H Biomedical is an innovative life-science company that discovers, develops and distributes human cell-based products and technologies for life science research, drug development and tissue engineering. We take pride in our contribution to improving human health and environment.

Our mission is to help scientists be more productive, more competitive and more innovative.

Serving the global research community, biotech sector and pharmaceutical industry. We supply more than 260 different types of primary human cells, media and cell-based products.

R&D projects:

EUROSTARS: PREVAIL
Preclinical development of novel ERRalpha inhibitors for treatment of Triple Negative Breast Cancer. The PREVAIL project will deliver a first-in-class targeted therapeutic for treatment of triple negative breast cancer (TNBC).


SEAL OF EXCELLENCE

Next generation of targeted dendritc cell vaccine for cancer treatment, a therapeutic cancer vaccine technology platform.

We are actively seeking partners in the pharmaceutical industry and clinical centres in order to co-develop our patented vaccine technology.

Founded in 2006, Abyntek Biopharma S.L. is a private Spanish company aimed at providing an integral and personalized service in the supply of antibodies.
Our company has two main business lines. On one hand, we are distributors of over twenty companies offering a comprehensive catalogue of more than 2 million antibodies, ELISA kits and proteins in general. On the other hand, we are the Spanish leading provider of custom monoclonal and polyclonal antibodies for R&D use. To this end, Abyntek can synthesize the necessary antigens (proteins and peptides) or make use of the client´s. We also offer antibody modifications such as biotinylation or conjugation to fluorophores and enzymes.
Come to visit our webpage (www.abyntek.com) and learn more about us. If you have any antibodies need, our international scientific team will be glad to help you!
Contact us and enjoy the experience of a special treat.

Abyntek on Twitter: bit.ly/1rummfr

ADC Biotechnology Ltd was founded in 2010 to develop and commercialise next generation conjugation technologies to the Antibody Drug Conjugate market. Bioconjugation using our proprietary 'Lock-Release'​ technology involves conjugation of proteins that are immobilised on solid supports, which delivers a number of key product advantages from minimal aggregate formation to minimal residual free drug and enhanced yields. From basic R&D applications through to improved supply economics and product risk management application of our 'Lock-Release'​ platform drives value through better products delivered with greater efficiency.

In addition to technology development, ADC Biotechnology offers a range of technical services, including conjugation (conventional and Lock-Release) to a variety of toxin payloads, toxin-linker design and synthesis and supply of ADCs for proof of concept and toxicology testing.

For more information on our services and Lock Release please visit

www.adcbio.com

AltraBio is an R&D company for analysis and interpretation of biomedical data in both preclinical and clinical development and for development of analytic and predictive tools. AltraBio is particularly focused on OMICS technologies (genomics, transcriptomics, proteomics etc.) and flow/mass cytometry with the goal of unlocking the value captured in large scale data set generated in life science experimental studies.

AltraBio's work flow covers the part of the R&D process following the generation of data in the experiment. This includes extensive data quality control, normalization, statistical analysis (using nonsupervised and supervised approaches) and their management, visualization and extensive exploration.

In contrast to a pure biostatistics consultancy, AltraBio performs a full-fledged biological interpretation of the analysis results in the context of current biomedical knowledge and generates a report that includes deep bibliography review and biological pathway analysis.

AltraBio applies the state-of-the-art knowledge in biomedicine and bioinformatics to inform both development of informatics tools used in its work and the analysis and interpretation of the experimental data sets.

Also, AltraBio has developed a proprietary tool for the automation of the tedious manual gating in cytometry approaches. This machine learning approach allows the application of a predetermined gating strategy while saving study time/cost and enhancing robustness. The use of this technique is helpful for studies with a high number of samples to treat one by one during a long time or in a batch process and its compatibility with GcLP allows its use in clinical trials.

anacura is an independent analytical centre of excellence in healthcare and drug development. Your go-to provider for top quality laboratory solutions delivered with a great human touch.

AnaBioTec provides analytical solutions (R&D and GMP) for pharma, biopharma, cell & gene therapy developers. Our GMP compliant platform is your reliable partner for end-to end analytical solutions for CMC activities from pre-clinical development, over in all phases of drug development until the lifecycle of commercial products. We deliver analytical techniques for identity, purity, quantity, quality, and potency testing according to the ICH guidelines. Our experts have a proven track record in method development and validation. Our in-house analytical expertise (+ 20 years) in combination with our operational performance helps saving time and shortens time to the market. Complemented with solid advice and effective scientific project management, we anticipate changing priorities and safeguard your milestones and timing.

Labo Nuytinck is specialized in evidence-based laboratory medicine and pathology of human tissue and biological samples. Our priority is to provide physicians with timely and accurate diagnostic support, together with personal advice and expertise in the interpretation of test results to guide therapeutic decisions.